{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-012879","form_type":"8-K","ticker":null,"cik":"0001845459","company_name":"NKGen Biotech, Inc.","filed_at":"2026-02-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.515440+00:00","generated_at":"2026-05-16T04:32:36.058593+00:00","sec_items":["1.01","2.03","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"NKGen Biotech obtains additional $251K loan, secured note now $26.8M","bullets":["Entered third amendment to secured promissory note with AlpineBrook Capital for additional $251,000 loan.","Total principal amount of secured promissory note increased to $26,758,106.","Interest on the new loan begins accruing from January 30, 2026, the funding date.","Loan is part of a series of amendments; prior principal was $26,507,106 after second amendment."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-012879","json":"https://secwatch.observer/filing/0001213900-26-012879.json","markdown":"https://secwatch.observer/filing/0001213900-26-012879.md","text":"https://secwatch.observer/filing/0001213900-26-012879.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1845459/000121390026012879/0001213900-26-012879-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1845459/000121390026012879/ea0275350-8k_nkgen.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T04:32:36.058593+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"298969fe566e4e800ecec739daa3d16d04a39f70","claim":"NKGen Biotech, Inc. incurred loan of $251,000 with AlpineBrook Capital GP I Limited.","evidence_excerpt":"The Alpine Third Amendment provides an additional $251,000 of funding to the Borrowers (the \"Fourth Additional New Loan\").","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1845459/000121390026012879/0001213900-26-012879-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"$251,000"},{"label":"Counterparty","value":"AlpineBrook Capital GP I Limited"},{"label":"Event","value":"incurrence"}]},{"claim_id":"a50be02b849abcb534b32422913547e686e28e4a","claim":"NKGen Biotech, Inc. amended Alpine Third Amendment with AlpineBrook Capital GP I Limited valued at $251,000 (effective 2026-01-30).","evidence_excerpt":"On January 30, 2026, NKGen Biotech, Inc. (the “Company”) and NKGen Operating Biotech, Inc., a Delaware corporation (together with the Company, the “Borrowers”), entered into a third amendment (the “Alpine Third Amendment”) to that certain secured promissory note with AlpineBrook Capital GP I Limited, dated January 5, 2026","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1845459/000121390026012879/0001213900-26-012879-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"AlpineBrook Capital GP I Limited"},{"label":"Value","value":"$251,000"},{"label":"Effective","value":"2026-01-30"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}